Basal cell carcinoma

BCC · Oncology · 1 drugs · 1 indications

Most common skin cancer. Locally advanced or metastatic BCC requires systemic therapy.

Competitive Landscape (1 drugs)

Drug	Company	Mechanism	Modality	Route	Stage
Libtayo	REGN	PD-1 inhibitor	Monoclonal antibody	IV	APPROVED

Indications (1)

Locally advanced basal cell carcinoma (post-hedgehog inhibitor)

Libtayo APPROVED

Data from Supabase · Updated 2026-03-24